Revisiting the role of erythropoietin for treatment of ocular disorders

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2016-10, Vol.30 (10), p.1293-1309
Main Authors: Shirley Ding, S L, Leow, S N, Munisvaradass, R, Koh, E H, Bastion, M L C, Then, K Y, Kumar, S, Mok, P L
Format: Article
Language:English
Subjects:
631/80/304
692/699/3161
Erythropoietin - physiology
Erythropoietin - therapeutic use
Eye Diseases - drug therapy
Eye Diseases - etiology
Eye Diseases - physiopathology
Eye Diseases - prevention & control
Humans
Laboratory Medicine
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Review
Surgery
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.
ISSN:0950-222X
1476-5454
DOI:10.1038/eye.2016.94